← Human Trials & Peer-Reviewed Studies
A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction.
Plain-language guide to PMID 20491724 (2010): randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 11 participants.
Key Facts
- PMID
- 20491724
- Journal
- Addiction (Abingdon, England)
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- McRobbie H et al. (8 authors)
- DOI
- 10.1111/j.1360-0443.2010.02950.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
Who Took Part
The abstract describes 11 participants taking part.
By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
Participants rated their urges to smoke, irritability, concentration and restlessness before and during the first hour of product use on a 100-point scale.
A subsample of 11 participants provided blood samples for nicotine analysis.
How the Study Was Run
The design is described as randomized, placebo-controlled and crossover.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.
In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Administration, Buccal, Nicotine, Nicotinic Agonists, Patient Satisfaction, Smoking, Smoking Cessation and Substance Withdrawal Syndrome.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of Therapeutic nicotine (patch, non-peptide) in 11 participants.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2010 (Addiction (Abingdon, England)), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.